Clinical Trials Logo

Relapsed Non Hodgkin Lymphoma clinical trials

View clinical trials related to Relapsed Non Hodgkin Lymphoma.

Filter by:

NCT ID: NCT05746858 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)

MIMOSA
Start date: April 1, 2023
Phase:
Study type: Observational

The goal of this study is to identify biomarkers that will predict outcome to standard and targeted therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The specific aims of the present project are: 1. To explore associations between expression of target antigens on surface of neoplastic cells of DLBCL patients and response to target therapies 2. To identify specific miRNA signatures as predictors of response to upfront and salvage immune-chemotherapies in DLBCL patients. 3. To refine the diagnosis and molecular profiling of DLBCL, and to provide biological information of prognostic relevance in the setting of innovative treatments of patients with DLBCL.

NCT ID: NCT05691153 Recruiting - B Cell Lymphoma Clinical Trials

ThisCART19A for B-NHL Relapsed After Auto-CAR T

Start date: December 1, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1, single-center, dose selection study to evaluate the efficacy, safety, and pharmacokinetics of ThisCART19A (allogeneic CAR-T targeting CD19) in patients with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma.

NCT ID: NCT05621096 Recruiting - Follicular Lymphoma Clinical Trials

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Start date: March 21, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to learn about treatment for people with B-cell lymphoma that did not respond to treatment or that has gotten worse after treatment. The aim of this trial is to answer the following questions: - If it is realistic to give people radiation treatment before they receive a chimeric antigen receptor (CAR) T-cell treatment for their cancer - If it is safe to give people radiation treatment before they receive a CAR T-cell treatment for their cancer

NCT ID: NCT05420493 Recruiting - Clinical trials for Non Hodgkin Lymphoma

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Start date: September 6, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and efficacy of CAR-T infusion preparation in the treatment of CD19-positive relapsed/refractory non-Hodgkin lymphoma.

NCT ID: NCT05332054 Enrolling by invitation - Lymphoma Clinical Trials

Long-Term Follow-up Study

LTFS
Start date: March 16, 2022
Phase:
Study type: Observational

This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients who have participated in a prior Caribou-sponsored clinical study, in a special access program, or in another study such as an IIT. Its purpose of is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies.

NCT ID: NCT05260957 Recruiting - Clinical trials for Refractory Non-Hodgkin Lymphoma

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Start date: December 14, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to test if a combination treatment of chimeric antigen receptor (CAR) T-cell therapy, Mosunetuzumab, and Polatuzumab Vedotin will result in tumor reduction.

NCT ID: NCT05053659 Recruiting - Clinical trials for Refractory Non-Hodgkin Lymphoma

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Start date: June 20, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the correct dose and safety of combining two new cancer drugs, loncastuximab tesirine and venetoclax, as a treatment for relapsed or refractory B cell lymphoma.These drugs are used to treat some lymphomas, but have not yet been tested in combination for the treatment of lymphoma. The main goal of this study is to determine the safety of the combination.

NCT ID: NCT05006534 Completed - Refractory Lymphoma Clinical Trials

Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma

Start date: June 1, 2020
Phase:
Study type: Observational

This study enrolled patients with relapsed or refractory diffuse large B cell lymphoma treated with polatuzumab vedotin-based chemoimmunotherapies. Patients were allowed to use chemotherapy regimens other than Rituximab and Bendamustine and transplantation following polatuzumab vedotin was also allowed.

NCT ID: NCT04978779 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Start date: December 16, 2021
Phase: Phase 1
Study type: Interventional

Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 as monotherapy or in combination with a BTKi in patients with Chronic Lymphocytic Leukemia (CLL) or Richter Syndrome

NCT ID: NCT04923789 Recruiting - Clinical trials for Refractory Non-Hodgkin Lymphoma

A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma

Start date: September 1, 2020
Phase:
Study type: Observational

This is a single center, prospective cohort study to to evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation(ASCT) bridging chimeric antigen receptor T (CART) cell therapy in the treatment of relapsed/refractory B-cell non-Hodgkin's lymphoma.